1. Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma
- Author
-
Hardy, Juliette, Boralevi, Franck, Mallet, Stephanie, Cabrera, Natalia, Belot, Alexandre, Phan, Alice, Barbarot, Sébastien, Duriez-Lasek, Audrey, Chiaverini, Christine, Hubiche, Thomas, Mahe, Emmanuel, Begon, Edouard, Bourrat, Emmanuelle, Boccara, Olivia, Aubert, Hélène, Lerosey, Martine Grall, Droitcourt, Catherine, Piram, Maryam, Mazereeuw-Hautier, Juliette, Research Group of the French Society of Paediatric Dermatology (SDFP in French), ., Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Université de Bordeaux (UB), Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Femme Mère Enfant, Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-Vincent de Paul, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Intercommunal, Hôpital d'Argenteuil, Université de Cergy Pontoise (UCP), Université Paris-Seine, AP-HP Hôpital universitaire Robert-Debré [Paris], CHU Necker - Enfants Malades [AP-HP], CHU Rouen, Normandie Université (NU), CHU Pontchaillou [Rennes], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), and Hardy, Juliette
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Adolescent ,morphea ,Drug Resistance ,Médecine humaine et pathologie ,Dermatology ,Scleroderma ,03 medical and health sciences ,Localised scleroderma ,Scleroderma, Localized ,0302 clinical medicine ,Internal medicine ,lcsh:Dermatology ,medicine ,Juvenile ,Humans ,scleroderma ,Localized Scleroderma ,Paediatric dermatology ,Child ,Retrospective Studies ,Dermatologie ,030203 arthritis & rheumatology ,localized scleroderma ,methotrexate ,treatment ,business.industry ,Infant ,General Medicine ,lcsh:RL1-803 ,medicine.disease ,Rheumatology ,3. Good health ,030104 developmental biology ,Methotrexate ,Child, Preschool ,Human health and pathology ,Female ,Dermatologic Agents ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology ,Morphea ,medicine.drug - Abstract
International audience; Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho-trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Metho-trexate dosage ranged from 7 to 15 mg/m2/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho-trexate and we did not identify a clinical profile for those resistant patients.
- Published
- 2019
- Full Text
- View/download PDF